Stephen Warren
10Patents
5h-index
17Co-inventors
59Inventor score
Filing activity: May 24, 1991 → Dec 17, 2004
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6610841B1 | Nucleotide-based prodrugs | Human Necessities | 20 | Expired |
| US6232071A | Tenascin-C nucleic acid ligands | Physics | 12 | Expired |
| US6890931B2 | Methods of treating disorders with group I mGluR antagonists | Human Necessities | 8 | Expired |
| US6916821B2 | Methods of treating disorders with Group I mGluR antagonists | Human Necessities | 7 | Expired |
| US6180337A | Diagnosis of the fragile X syndrome | Chemistry; Metallurgy | 5 | Expired |
| US6107025A | Diagnosis of the fragile X syndrome | Chemistry; Metallurgy | 5 | Expired |
| US6596491B2 | Tenascin-C nucleic acid ligands | Physics | 4 | Expired |
| US7005260B1 | Tenascin-C nucleic acid ligands | Chemistry; Metallurgy | 3 | Expired |
| US7648993B2 | Methods of treating disorders with Group I mGluR antagonists | Human Necessities | 3 | Active |
| US7432052B2 | Method and identification of downstream mRNA ligands to FMRP and their role in fragile X syndrome and associated disorders | Chemistry; Metallurgy | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.